Axel Linke
Latest contributions
Impact of guideline-directed medical therapy on long-term outcome after tricuspid TEER
15 Dec 2025
A 79-year-old woman with advanced right heart failure (NYHA III) was referred after repeated hospitalisations for decompensation despite optimal medical therapy. Echocardiography revealed torrential functional tricuspid regurgitation with suitable anatomy for T-TEER. Given her high surgical risk (TRISCORE 7/12) and borderline pulmonary hypertension, how would you...
Author
Author
TAVI in bicuspid aortic valve disease
22 May 2025 – From EuroPCR 2025
Explore the unique challenges of TAVI in bicuspid aortic valve disease with a focus on long-term outcomes, residual gradients, prosthesis-patient mismatch, and anatomical subtype comparisons. This session draws on international registry data to inform clinical decision-making and optimize procedural strategies in this complex patient population.
Management of challenging TAVI device delivery
22 May 2025 – From EuroPCR 2025
Explore innovative solutions for managing challenging TAVI device delivery. This session presents cases involving kinked and stuck Navitor valves, the use of snare devices for retrieval, balloon-expandable TAVI in severe bicuspid aortic stenosis, and alternative access routes such as transaortic access after failed transfemoral valve-in-valve procedures.
Align for the future with case-based discussions on next generation balloon expandable transcatheter heart valve technology
16 May 2024 – From EuroPCR 2024
Join this EuroPCR 2024 session to delve into the cutting-edge innovations and techniques shaping transcatheter heart valve interventions. Witness firsthand the versatility of the Myval Octacor THV platform, navigating through challenging scenarios with ease, explore the significance of lifetime patient management in TAVI, unveiling the novel...
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
Pushing the limits of transcatheter mitral valve interventions
15 May 2024 – From EuroPCR 2024
This session features selected EuroPCR 2024 Clinical Case submissions showcasing the latest advancements and challenges in transcatheter mitral valve interventions. Experts will present and discuss complex cases involving severely calcified mitral valves, mitral valve-in-ring implantations, and the management of mitral regurgitation associated with hypertrophic obstructive cardiomyopathy....
Addressing remaining issues after TAVI: what to expect from the new generation?
21 Nov 2023 – From PCR London Valves 2023
Consult this session if you want to discuss the challenges of TAVI for lower-risk patients, and to capture the features of new TAVI devices.
Hot TAVI topics - Cerebral embolic protection
27 Nov 2022 – From PCR London Valves 2022
Consult this session to learn more about the latest data concerning cerebral embolic protection (CEP) in TAVI, to find out about currently available and emerging embolic protection devices and to get a better understanding of variations in head and neck vessel anatomy and tips and tricks...
